These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19782386)

  • 1. Leishmaniasis and biologic therapies for rheumatologic diseases.
    Cascio A; Iaria M; Iaria C
    Semin Arthritis Rheum; 2010 Dec; 40(3):e3-5. PubMed ID: 19782386
    [No Abstract]   [Full Text] [Related]  

  • 2. Infectious complications of biological therapy.
    Haroon N; Inman RD
    Curr Opin Rheumatol; 2009 Jul; 21(4):397-403. PubMed ID: 19412102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of infections with biologic therapies for rheumatoid arthritis.
    Furst DE
    Semin Arthritis Rheum; 2010 Apr; 39(5):327-46. PubMed ID: 19117595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention.
    Winthrop KL
    Rheum Dis Clin North Am; 2012 Nov; 38(4):727-45. PubMed ID: 23137579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritis].
    Baixauli Rubio A; Rodríguez Górriz E; Campos Fernández C; Calvo Catalá J; García Vicente S
    An Med Interna; 2003 May; 20(5):276-7. PubMed ID: 12831311
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies.
    Calabrese LH; Molloy ES
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii64-5. PubMed ID: 19022817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature.
    Antinori S; Calattini S; Longhi E; Bestetti G; Piolini R; Magni C; Orlando G; Gramiccia M; Acquaviva V; Foschi A; Corvasce S; Colomba C; Titone L; Parravicini C; Cascio A; Corbellino M
    Clin Infect Dis; 2007 Jun; 44(12):1602-10. PubMed ID: 17516404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Legionellosis and biologic therapies.
    Bodro M; Carratalà J; Paterson DL
    Respir Med; 2014 Aug; 108(8):1223-8. PubMed ID: 24975288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-sectional screening study for Leishmania DNA and antibodies in biologic-treated patients with psoriasis living in an area endemic for leishmaniasis.
    Kurizky PS; Gomes CM; Cesetti MV; Martins GA; Regattieri NAT; Marianelli FF; Sevilha Santos L; Medeiros Silva V; de Paula NA; Frade MAC; da Silva EF; da Mota LMH
    Br J Dermatol; 2019 Dec; 181(6):1337-1339. PubMed ID: 31260088
    [No Abstract]   [Full Text] [Related]  

  • 10. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.
    Vassilopoulos D; Calabrese LH
    Curr Opin Rheumatol; 2007 Nov; 19(6):619-25. PubMed ID: 17917544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmania and HIV co-infection.
    Lepr Rev; 2000 Mar; 71(1):104-5. PubMed ID: 10821001
    [No Abstract]   [Full Text] [Related]  

  • 12. Biologic therapy in clinical practice: enthusiasm must be tempered by caution.
    Moots R; Taggart A; Walker D
    Rheumatology (Oxford); 2003 May; 42(5):614-6. PubMed ID: 12709535
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologic targeted therapies in pediatric rheumatology.
    Guillaume-Czitrom S;
    Joint Bone Spine; 2014 Feb; 81 Suppl 1():2-48. PubMed ID: 24661916
    [No Abstract]   [Full Text] [Related]  

  • 14. An investigation of Leishmania spp. in Didelphis spp. from urban and peri-urban areas in Bauru (São Paulo, Brazil).
    Santiago ME; Vasconcelos RO; Fattori KR; Munari DP; Michelin Ade F; Lima VM
    Vet Parasitol; 2007 Dec; 150(4):283-90. PubMed ID: 17996372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of biologic therapy in rheumatoid arthritis.
    Woodrick RS; Ruderman EM
    Nat Rev Rheumatol; 2011 Oct; 7(11):639-52. PubMed ID: 21989284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatological patients undergoing immunosuppressive treatments and parasitic diseases: a review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections.
    Fabiani S; Bruschi F
    Clin Exp Rheumatol; 2014; 32(4):587-96. PubMed ID: 25065776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network.
    Winthrop KL; Yamashita S; Beekmann SE; Polgreen PM;
    Clin Infect Dis; 2008 Jun; 46(11):1738-40. PubMed ID: 18419421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of canine leishmaniasis: conventional and molecular techniques using different tissues.
    Maia C; Ramada J; Cristóvão JM; Gonçalves L; Campino L
    Vet J; 2009 Jan; 179(1):142-4. PubMed ID: 17936654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic therapy for autoimmune diseases: an update.
    Rosman Z; Shoenfeld Y; Zandman-Goddard G
    BMC Med; 2013 Apr; 11():88. PubMed ID: 23557513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic agents and their use in resource-poor countries.
    Adebajo A; Fursts DE
    J Rheumatol; 2005 Jul; 32(7):1182-3. PubMed ID: 15996048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.